Rapport Therapeutics, Inc. Common Stock (RAPP)
NASDAQ • Healthcare
Last close at October 27, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Rapport Therapeutics’ second fiscal quarter of 2026 results (based on preliminary figures reported August 5, 2026) missed expectations on EPS, with EPS of -$1.19 trailing the -$1.12 estimate by -$0.07, as the CNS-focused biotech continued to run operating losses tied to advancing its pipeline, including the RAP-219 program for indications such as epilepsy and pain. The company posted a GAAP net loss of roughly $56.6 million, down 111.8% year over year from a net loss of about $26.7 million a year ago, while operating income was about -$60.8 million. On the bottom line, EPS was down 58.7% from -$0.75 a year earlier. Cash generation remained negative, with operating cash flow of roughly -$41.5 million during the quarter. For the next period, consensus calls for EPS of -$1.21.
Next report — what to expect
Rapport Therapeutics, Inc. (RAPP) reports earnings on November 5, 2026. Wall Street’s consensus calls for EPS of -$1.21. On results history, the company has beaten EPS in 6 of 8 most recent quarters, so traders may focus on whether EPS lands above or below that benchmark.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. is a small-cap biotechnology company listed on the NASDAQ as RAPP that discovers and develops small-molecule medicines for central nervous system disorders. The company works in drug development rather than commercial sales, with a pipeline centered on targeted therapies for epilepsy, pain, bipolar disorder, and hearing-related conditions.
Today's Snapshot
The day ended with RAPP 8.7% higher at 27.54, while its sector was flat. Trading was lighter than usual, with volume about a third of its usual level. Earnings are due from RAPP on 5 November.
Trading Volume
Below 10d avg (1.6M)
553.9K
vs S&P 500 Today
Strong Outperformance
+8.03%
Updated: October 27, 2026 at 20:32 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$27.51 - $36.87Sell
- RSI (14)38.40Neutral
- Stochastic %K (14, 3, 3)22.02Neutral
- MACD Level (12, 26)-3.16Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.